BRPI0922305A2 - composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida - Google Patents

composições antitumorais contendo anticorpos que reconhecem, especialmente, cd38 e ciclofosfamida

Info

Publication number
BRPI0922305A2
BRPI0922305A2 BRPI0922305A BRPI0922305A BRPI0922305A2 BR PI0922305 A2 BRPI0922305 A2 BR PI0922305A2 BR PI0922305 A BRPI0922305 A BR PI0922305A BR PI0922305 A BRPI0922305 A BR PI0922305A BR PI0922305 A2 BRPI0922305 A2 BR PI0922305A2
Authority
BR
Brazil
Prior art keywords
cyclophosphamide
compositions containing
containing antibodies
antitumor compositions
recognize especially
Prior art date
Application number
BRPI0922305A
Other languages
English (en)
Inventor
Pascale Lejeune
Patricia Vrignaud
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of BRPI0922305A2 publication Critical patent/BRPI0922305A2/pt
Publication of BRPI0922305B1 publication Critical patent/BRPI0922305B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/664—Amides of phosphorus acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
BRPI0922305-3A 2008-11-28 2009-11-27 Combinações farmacêuticas contendo ciclofosfamida e anticorpos que reconhecem especificamente cd38, bem como seus usos BRPI0922305B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08291119.9 2008-11-28
EP08291119A EP2191843A1 (en) 2008-11-28 2008-11-28 Antitumor combinations containing antibodies recognizing specifically CD38 and cyclophosphamide
PCT/IB2009/055392 WO2010061360A1 (en) 2008-11-28 2009-11-27 Antitumor combinations containing antibodies recognizing specifically cd38 and cylophosphamide

Publications (2)

Publication Number Publication Date
BRPI0922305A2 true BRPI0922305A2 (pt) 2016-06-21
BRPI0922305B1 BRPI0922305B1 (pt) 2022-04-05

Family

ID=40637068

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0922305-3A BRPI0922305B1 (pt) 2008-11-28 2009-11-27 Combinações farmacêuticas contendo ciclofosfamida e anticorpos que reconhecem especificamente cd38, bem como seus usos

Country Status (29)

Country Link
US (2) US20110305690A1 (pt)
EP (2) EP2191843A1 (pt)
JP (3) JP2012510464A (pt)
KR (1) KR101749770B1 (pt)
CN (1) CN102264387B (pt)
AR (1) AR074221A1 (pt)
AU (1) AU2009321252B2 (pt)
BR (1) BRPI0922305B1 (pt)
CA (1) CA2745012C (pt)
CL (1) CL2011001256A1 (pt)
CO (1) CO6361947A2 (pt)
CR (1) CR20110283A (pt)
EA (2) EA032934B1 (pt)
EC (1) ECSP11011077A (pt)
HN (1) HN2011001426A (pt)
MA (1) MA32894B1 (pt)
ME (1) ME01139B (pt)
MX (1) MX340062B (pt)
MY (1) MY166530A (pt)
NI (1) NI201100104A (pt)
NZ (1) NZ593147A (pt)
PA (1) PA8850201A1 (pt)
PE (1) PE20110822A1 (pt)
SV (1) SV2011003925A (pt)
TW (1) TWI457346B (pt)
UA (1) UA104161C2 (pt)
UY (1) UY32267A (pt)
WO (1) WO2010061360A1 (pt)
ZA (1) ZA201103920B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2191840A1 (en) 2008-11-28 2010-06-02 Sanofi-Aventis Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan
US8877899B2 (en) 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HRP20171964T1 (hr) * 2012-09-25 2018-02-23 Morphosys Ag Kombinacije i njihova upotreba
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
MX373301B (es) 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
US9732154B2 (en) 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US10617757B2 (en) 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
WO2016040294A2 (en) 2014-09-09 2016-03-17 Janssen Biotech, Inc. Combination therapies with anti-cd38 antibodies
PE20171094A1 (es) 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
CR20170526A (es) 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
CN107708734B (zh) 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
JP7027321B2 (ja) 2015-11-03 2022-03-01 ヤンセン バイオテツク,インコーポレーテツド 抗cd38抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2018002181A1 (en) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. TREATMENT OF IgE-MEDIATED DISEASES WITH ANTIBODIES THAT SPECIFICALLY BIND CD38
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
TWI924633B (zh) 2019-03-15 2026-05-11 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
AU2020397170A1 (en) 2019-12-05 2022-07-21 Sanofi-Aventis U.S. Llc Formulations of anti-CD38 antibodies for subcutaneous administration
EP4277930A1 (en) 2021-01-14 2023-11-22 MorphoSys AG Anti-cd38 antibodies and their uses
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗cd38抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1996034096A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
EP1972194A1 (en) 1996-12-03 2008-09-24 Amgen Fremont Inc. Transgenic mammals having human ig loci including plural vh and vk regions and antibodies produced therefrom
JP3876002B2 (ja) 1997-04-14 2007-01-31 ミクロメート・アクチエンゲゼルシャフト 抗ヒト抗原受容体を産生するための斬新な方法およびそれらの使用
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
AU770718B2 (en) * 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
GB0221574D0 (en) * 2002-09-17 2002-10-23 Isis Innovation Treatments
EP2551282A3 (en) * 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
EP1914242A1 (en) * 2006-10-19 2008-04-23 Sanofi-Aventis Novel anti-CD38 antibodies for the treatment of cancer
AU2009206506B2 (en) * 2008-01-23 2013-01-10 Xencor, Inc. Optimized CD40 antibodies and methods of using the same
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб

Also Published As

Publication number Publication date
MA32894B1 (fr) 2011-12-01
MY166530A (en) 2018-07-10
ME01139B (me) 2013-03-20
EA201692041A1 (ru) 2017-05-31
BRPI0922305B1 (pt) 2022-04-05
US20170056496A1 (en) 2017-03-02
PE20110822A1 (es) 2011-11-22
JP2015120729A (ja) 2015-07-02
EA032934B1 (ru) 2019-08-30
UY32267A (es) 2010-06-30
JP6018235B2 (ja) 2016-11-02
JP6215429B2 (ja) 2017-10-18
CO6361947A2 (es) 2012-01-20
EP2191843A1 (en) 2010-06-02
SV2011003925A (es) 2011-10-07
EA201100869A1 (ru) 2011-10-31
CR20110283A (es) 2011-09-20
AR074221A1 (es) 2010-12-29
PA8850201A1 (es) 2010-07-27
TW201024315A (en) 2010-07-01
US20110305690A1 (en) 2011-12-15
EA026008B1 (ru) 2017-02-28
CL2011001256A1 (es) 2012-01-27
CA2745012A1 (en) 2010-06-03
HN2011001426A (es) 2014-01-13
NI201100104A (es) 2011-09-26
CA2745012C (en) 2020-09-15
KR20110096552A (ko) 2011-08-30
NZ593147A (en) 2012-12-21
AU2009321252A1 (en) 2010-06-03
WO2010061360A1 (en) 2010-06-03
AU2009321252B2 (en) 2016-06-09
EP2370097A1 (en) 2011-10-05
JP2017036297A (ja) 2017-02-16
MX2011005538A (es) 2011-10-10
TWI457346B (zh) 2014-10-21
MX340062B (es) 2016-06-23
KR101749770B1 (ko) 2017-06-22
HK1164154A1 (en) 2012-09-21
ZA201103920B (en) 2012-09-26
CN102264387A (zh) 2011-11-30
JP2012510464A (ja) 2012-05-10
CN102264387B (zh) 2015-04-08
ECSP11011077A (es) 2011-07-29
EP2370097B1 (en) 2019-01-09
UA104161C2 (uk) 2014-01-10

Similar Documents

Publication Publication Date Title
PT2370096T (pt) Combinações antitumorais contendo anticorpos que reconhecem especificamente cd38 e citarabina
BRPI0922304A2 (pt) combinações antitumorais contendo anticorpos que especificamente reconhecem cd38 e vincristina
NI201100104A (es) Combinaciones antitumorales que contienen anticuerpos que reconocen específicamente cd38 y ciclofosfamida.
BRPI0915824A2 (pt) Composição nutricional contendo mistura de oligossacarídeos
AP2010005424A0 (en) Assays.
BRPI0814745A2 (pt) Composição de produto.
BR112012003977A2 (pt) composições que induzem ajuda de célula t
BRPI0919800A2 (pt) embalagem
ES2703158T8 (es) Composiciones farmacéuticas que comprenden oxi-hidróxido de hierro
BR112013014370A2 (pt) combinações antitumor que contêm anticorpos que reconhecem especificamente cd38 e bortezomib
PH12013500886A1 (en) Pesticidal compositions and processes related thereto
IT1394472B1 (it) Tavolo per riunioni.
NO20092622L (no) Hydrokarbongassbearbeidng
BRPI0920653A2 (pt) embalagem
BRPI0821907A2 (pt) Composições de siloxano
BRPI0923428A2 (pt) refinaria de gás integrada
BRPI0906812A2 (pt) Mitigação de reluzência do lcd.
BR112012012890A2 (pt) misturas estabilizadas que contêm modificadores de fricção.
DE602008004219D1 (de) Packung für rauchartikel
BRPI0914940A2 (pt) composições nutritivas contendo punicalaginas
IL219470A (en) Antibacterial antibody, preparations containing it and its uses
BRPI0906828A2 (pt) Embalagem
BRPI0907448A2 (pt) Instrumentos.
PT2362778T (pt) Composições que compreendem vitamina c
EP2167674A4 (en) FOOD COMPOSITION

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 27/11/2009, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.

B25G Requested change of headquarter approved

Owner name: SANOFI (FR)